Bradykinin-induced preconditioning in patients undergoing coronary angioplasty  by Leesar, Massoud A. et al.
CLINICAL STUDIES Interventional Cardiology
Bradykinin-Induced Preconditioning in
Patients Undergoing Coronary Angioplasty
Massoud A. Leesar, MD, FACC, Marcus F. Stoddard, MD, FACC, Srinivas Manchikalapudi, MD,
Roberto Bolli, MD, FACC
Louisville, Kentucky
OBJECTIVES The purpose of this study was to determine whether administration of bradykinin reproduces
the cardioprotective effects of ischemic preconditioning (PC) in patients undergoing
percutaneous transluminal coronary angioplasty (PTCA).
BACKGROUND Experimental studies suggest that activation of the bradykinin B2 receptor is an important
trigger of ischemic PC. However, it is unknown whether bradykinin can precondition human
myocardium against ischemia in vivo. Multicenter clinical trials have demonstrated an
anti-ischemic effect of angiotensin-converting enzyme inhibitors, which has been postulated
to result from potentiation of bradykinin; however, direct evidence for an anti-ischemic action
of bradykinin in patients is lacking.
METHODS Thirty patients were randomized to receive a 10-min intracoronary infusion of bradykinin
(2.5 mg/min) or normal saline. Ten minutes later they underwent PTCA (three 2-min
balloon inflations 5 min apart).
RESULTS In control patients, the ST-segment shift on the intracoronary and surface electrocardiogram
was significantly greater during the first inflation than during the second and third inflations,
consistent with ischemic PC. In bradykinin-treated patients, the ST-segment shift during the
first inflation was significantly smaller than in the control group, and there were no
appreciable differences in ST-segment shift during the three inflations. Measurements of
chest pain score and regional wall motion during inflation (quantitative two-dimensional
echocardiography) paralleled those of ST-segment shift. Infusion of bradykinin had no
hemodynamic effects and no significant adverse effects. Thus, intracoronary infusion of
bradykinin before PTCA rendered the myocardium relatively resistant to subsequent
ischemia, and the degree of this cardioprotective effect was comparable to that afforded by the
ischemia associated with the first balloon inflation in control subjects. In a separate cohort of
seven patients given the same dose of bradykinin, coronary hyperemia resolved completely
within 10 min after the end of the infusion, indicating that bradykinin-induced vasodilation
cannot account for the protective effects observed during the first balloon inflation.
CONCLUSIONS Bradykinin preconditions human myocardium against ischemia in vivo in the absence of
systemic hemodynamic changes. Pretreatment with bradykinin appears to be just as effective
as ischemic PC and could be used prophylactically to attenuate ischemia in selected patients
undergoing PTCA. (J Am Coll Cardiol 1999;34:639–50) © 1999 by the American College
of Cardiology
Ischemic preconditioning (PC) is a powerful cardioprotec-
tive mechanism whereby brief episodes of ischemia enhance
the tolerance of the heart to subsequent ischemic insults
(1–4). Although considerable evidence supports the occur-
rence of ischemic PC in patients with coronary artery
disease (5), the mechanisms responsible for the development
of this mechanism in humans remain poorly understood.
Experimental studies suggest that an important trigger of
ischemic PC is the activation of bradykinin B2 receptors
(6–13). The involvement of bradykinin in ischemic PC is
supported by a number of experimental studies that have
demonstrated that local infusion of this peptide mimics the
cardioprotective effects of ischemic PC (6,7,10–12,14),
whereas the administration of bradykinin B2 receptor an-
tagonists prevents it (8–13). It was proposed that bradyki-
nin triggers ischemic PC by activating the endothelial cell
B2 receptor, which couples with protein kinase C and
initiates a signal transduction pathway analogous to that
initiated by adenosine (11). The bradykinin hypothesis of
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ischemic PC is further supported by the demonstration that
intracardiac production of this peptide increases during
myocardial ischemia (15,16).
Furthermore, it has been shown that direct intracoronary
infusion of bradykinin reduces infarct size in dogs (17). In
addition, the cardioprotective effects of inhibitors of the
angiotensin-converting enzyme (ACE) (kininase II) appear
to be due to inhibition of the breakdown of bradykinin,
because bradykinin antagonists can reverse them (17,18).
Although pharmacologic activation of either adenosine A1
(2,19,20) or bradykinin B2 (6,7,10–12,14) receptors can
induce a PC-like effect, at least under certain conditions the
activation of both receptors appears to be necessary to
trigger the protective effects of ischemic PC (11).
To date, evidence suggesting a role of bradykinin in
ischemic PC has been obtained in rabbits (10,11), rats (12)
and dogs (6–9). A study of isolated atrial trabeculae sub-
jected to substrate-free hypoxia with rapid pacing (21)
supports a role of bradykinin in triggering ischemic PC in
the human heart. However, because there are numerous
fundamental differences between substrate-free hypoxia of
isolated atrial trabeculae in vitro and ischemia of the intact
ventricle in vivo, data obtained in the former preparation
cannot necessarily be extrapolated to the latter setting.
Specifically, it remains unknown whether bradykinin can
precondition the intact human heart in vivo and, if so,
whether it can protect ventricular myocardium (as opposed
to atrium myocardium) against ischemia (as opposed to
substrate-free hypoxia in vitro). Accordingly, it is necessary
to explore the bradykinin hypothesis in the clinical setting.
To date, there is no report that bradykinin can precondition
human myocardium in vivo.
Elucidation of the effects of bradykinin on myocardial
ischemia in humans may also help to explain the mechanism
for the apparent cardioprotective effects of ACE inhibitors
in patients with coronary artery disease. Several multicenter
trials have demonstrated a beneficial effect of ACE inhibi-
tors in patients with coronary artery disease (22,23) and a
number of studies, such as SOLVD (Studies of Left
Ventricular Dysfunction) (24), SAVE (Survival and Ven-
tricular Enlargement) (25), and TRACE (Trandolapril
Cardiac Evaluation) (26), have shown that these agents
significantly diminish the occurrence of myocardial infarc-
tion and other ischemic end points. The mechanism for this
salutary action is unclear, but conceivably it may involve
attenuation of the degradation of bradykinin by ACE
(10,18,23,27–29). To our knowledge, no published studies
have directly assessed the effect of bradykinin on myocardial
ischemia in humans.
As a first step toward elucidating the role of bradykinin in
ischemic PC in humans, we tested the hypothesis that
pretreatment with this peptide, in the absence of ischemia,
induces a cardioprotective effect comparable to that induced
by ischemic PC in patients undergoing percutaneous trans-
luminal coronary angioplasty (PTCA). To this end, we
administered intracoronary bradykinin 10 min before
PTCA and determined whether the severity of ischemia
during the subsequent balloon inflations was attenuated as
compared with untreated control patients. In addition, we
determined whether the expected PC response (i.e., the
progressive decrease in ST-segment shift and chest pain
during subsequent balloon inflations) was abrogated by
pretreatment with bradykinin. We selected the setting of
PTCA because 1) considerable evidence supports the oc-
currence of ischemic PC during subsequent balloon infla-
tions (30–39); 2) this manifestation of PC has been char-
acterized more extensively than any other clinical
manifestation of PC (30–39); 3) unlike other clinical
settings, during PTCA the duration of ischemia can be
standardized and several clinical variables can be relatively
well controlled, and 4) patients can be pretreated. The
results demonstrate, for the first time, that bradykinin
protects the human heart against ischemia in vivo.
METHODS
Study population. The patient population consisted of 30
subjects referred for PTCA of an isolated obstructive lesion
(internal diameter reduction .70% by visual assessment) in
the proximal two-thirds of a major coronary artery. Patients
were prospectively selected on the basis of the following
criteria: 1) no angiographically visible collateral vessels; 2)
no history or electrocardiographic (ECG) evidence of prior
myocardial infarction in the territory supplied by the vessel
undergoing PTCA; 3) no wall-motion abnormalities in the
region subserved by the artery undergoing PTCA; 4)
normal left ventricular (LV) ejection fraction; 5) no con-
duction defects on the ECG; 6) no evidence of LV
hypertrophy on the echocardiogram; and 7) no baseline
ST-segment abnormalities on the surface or intracoronary
ECG. Fifteen patients were admitted with a diagnosis of
unstable angina, and the remaining 15 had clinically stable
angina pectoris (Table 1). The average interval between the
last episode of angina and PTCA was 6.2 6 1.1 days in
control subjects and 5.4 6 0.7 days in bradykinin-treated
patients. No patient had angina pectoris in the 48 h before
PTCA. On the LV angiogram, the ejection fraction was
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
DCI 5 digital cardiac imaging
ECG 5 electrocardiogram
LV 5 left ventricular
PC 5 preconditioning
PKC 5 protein kinase C
PTCA 5 percutaneous transluminal coronary
angioplasty
SAVE 5 Survival and Ventricular Enlargement
SOLVD 5 Studies of Left Ventricular Dysfunction
TRACE 5 Trandolapril Cardiac Evaluation
LAD 5 left anterior descending coronary artery
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55 6 2% in control patients and 54 6 3% in bradykinin-
treated patients (Table 1). This study was approved by the
Institutional Review Board on July 17, 1996; informed
consent, via an institutionally approved human investigation
form, was obtained in all patients.
Experimental protocol. In this single-blind study, patients
were randomly allocated either to a control or a bradykinin-
treated group. The control group consisted of 15 patients
(12 men and 3 women, ranging in age from 40 to 77 years;
mean age, 60 6 3 years); the bradykinin-treated group
consisted of 15 patients (11 men and 4 women, ranging in
age from 41 to 76 years; mean age, 59 6 3 years) (Table 1).
All patients were being treated with aspirin (325 mg/d) for
$48 h before PTCA; 22 patients (13 controls and 9
bradykinin-treated) were receiving long-acting nitrates, 15
(7 controls and 8 bradykinin-treated) were receiving beta-
blockers and 9 (5 controls and 4 bradykinin-treated) were
receiving calcium channel antagonists for $48 h before
PTCA (Table 1). Antianginal medications were not discon-
tinued before the procedure. Seven patients (two controls
and five bradykinin-treated) received IV nitroglycerin before
and throughout PTCA, and four patients (controls) re-
ceived intracoronary nitroglycerin (Table 1). All patients
were studied after an overnight fast and were premedicated
with midazolam (1 mg IV 10 min before the procedure).
The PTCA procedure was performed by a standard
technique using the femoral approach. After placement of
the guiding catheter and performance of baseline coronary
angiography, an IV bolus of 10,000 IU of heparin was
administered; additional boluses of heparin were given
during the procedure to achieve an activated clotting time of
.300 s. Nonionic contrast medium (lopamidol, Bracco
Diagnostics, New Brunswick, New Jersey; 796 mOsm/kg)
was used in all patients. After venous cannulation, a 5F
bipolar temporary transvenous pacemaker was advanced
under fluoroscopic guidance to the right ventricular apex
and set to demand mode for heart rate backup. A 2.2F
Tracker coronary-infusion catheter (Boston Scientific, Inc.,
Maple Grove, Minnesota) was advanced over a 0.014-inch
(0.036 cm) guide wire (Traverse wire, Advanced Cardiovas-
cular Systems, Santa Clara, California) into the proximal
portion of the coronary artery for selective intracoronary
infusion of bradykinin or saline. (Bradykinin was obtained
from Sigma F and D Division, St. Louis, Missouri.) A stock
solution was prepared in normal saline at a concentration of
12.5 mg/ml. The solution was sterilized by the School of
Pharmacy at the University of Kentucky.
On the day of the study, a sample of stock solution was
diluted in normal saline to a concentration of 25 mg in 50 ml
and infused at a rate of 2.5 mg/min over 10 min. This dose
of bradykinin was selected on the basis of pilot studies in
which an infusion of 5.0 mg/min was found to cause arterial
hypotension. The control group received an equivalent
volume of vehicle (normal saline). After infusion of either
bradykinin or vehicle, the Tracker catheter was removed.
After a 10-min drug-free period, the lesion was crossed with
a 0.014-inch (0.036 cm) guide wire. The PTCA was
performed with Boston Scientific, Inc. or Cordis balloon
dilation catheters ranging in diameter from 2.5 to 4.0 mm.
Balloon sizes were determined by examining normal regions
of the coronary artery adjacent to the stenosis. After the
balloon was positioned across the lesion, patients underwent
three balloon inflations, each lasting 120 s, interspersed with
5-min periods of reperfusion during which the balloon was
deflated and withdrawn proximal to the lesion with the
guide wire remaining across the lesion. Balloon inflation
pressures ranged from 4.0 to 10.0 atmospheres (atm). Five
minutes after the end of the third inflation, the study
protocol was terminated and decisions regarding further
inflations or other interventional procedures were made on
an individual basis.
Assessment of myocardial ischemia. Lead V5 of the
electrocardiographer (Hewlett-Packard, Model M1700 A)
was connected to the coronary guide wire. The intracoro-
nary ECG (derived from the guide wire) along with the
remaining 11 standard surface leads were recorded contin-
uously at a paper speed of 50 mm/s during the three balloon
inflations and at selected times after deflation. At all
Table 1. Clinical Features of the Two Groups of Patients
Control
Group
(n 5 15)
Bradykinin-
Treated
Group
(n 5 15)
Age (yr) 60 6 3 59 6 3
Gender (M/F) 12/3 11/4
Hypertension 10 13
Smoking 9 8
Diabetes mellitus 3 4
Previous CABG 0 0
Previous PTCA 2 5
Previous myocardial infarction in
non-PTCA territory
3 2
LV ejection fraction (%) 55 6 2 54 6 3
Anginal syndrome on admission
CCS Class 1–2 8 7
CCS Class 3–4 7 8
Interval between last episode of
angina and PTCA (days)
6.2 6 1.1 5.4 6 0.7
Intracoronary nitroglycerin
administration
Before first inflation 1 0
After first inflation 3 0
Antianginal medications
Intravenous nitroglycerin 2 5
Long-acting nitrates 13 9
Calcium channel-blocking agents 5 4
Beta-blocking agents 7 8
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous transluminal
coronary angioplasty; LV 5 left ventricular; CCS 5 Canadian Cardiovascular
Society.
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time-points, the ST-segment shift was measured 80 ms
after the J point on a minimum of three complexes. The
sums of the absolute values of the ST-segment shifts from
baseline on the surface ECGs and on the intracoronary
ECGs were calculated separately and expressed in millime-
ters (1 mm 5 0.1 mV). All ECG recordings were analyzed
by a cardiologist who had no knowledge of the study
protocol.
As elaborated elsewhere (39), there is considerable evi-
dence that changes in the ST-segment shift are a valid
marker of changes in the severity of myocardial ischemia.
For example, recent investigations in experimental animals
have demonstrated that the magnitude of the ST-segment
shift accurately reflects the presence and magnitude of the
infarct size limitation afforded by either ischemic (40) or
pharmacologic (41) PC. Furthermore, studies in patients
undergoing PTCA have shown that the ST-segment shift
correlates with both metabolic and contractile parameters of
myocardial ischemia—that is, with the magnitude of lactate
production (42) and regional wall-motion abnormalities
(43).
Assessment of chest pain. At the beginning of the proce-
dure, patients were informed that they may develop chest
pain during balloon inflations. At the end of each inflation,
the intensity of the cardiac pain was assessed using a
visual-analog scale (44). Patients were asked to put a mark
on a 100-mm scale marked from no symptoms [0] to the
most severe symptoms [100]. The intensity of the chest pain
was measured in millimeters from 0 to the subject’s mark.
Assessment of coronary blood flow and coronary collat-
erals. To determine whether the cardioprotective effects of
bradykinin could have been due to coronary vasodilation,
coronary blood flow was measured in an additional group of
seven patients. A 0.014-inch (0.036 cm) Doppler guide wire
(Flowire; Cardiometrics, Mountain View, California) was
advanced into the coronary artery and positioned distal to
the Tracker infusion catheter. Particular care was taken to
avoid placement into a side branch and to avoid post-
stenotic velocity jets. Baseline average peak velocity was
recorded. Once a stable, maximal Doppler signal correlated
with a crisp gray-scale Doppler envelope, as previously
described (45,46), was obtained, bradykinin was infused at a
rate of 2.5 mg/min for 10 min, and average peak velocity was
recorded again immediately after the end of infusion and
10 min after the end of infusion. Coronary angiograms were
performed at baseline, immediately after the infusion of
bradykinin and 10 min after the infusion of bradykinin
using an 8F guiding catheter. A single “working view” that
permitted clear visualization of the coronary segment with-
out foreshortening was selected for quantitative analysis.
The angiograms were recorded using a cineangiographic
system (Philips, Cincinnati, Ohio), and on-line quantitative
angiography was performed with the Philips Digital Car-
diac Imaging (DCI) Automated Coronary Analysis System,
as previously described (47). Coronary artery diameter was
measured in a 5-mm segment of vessel beginning 2.5 mm
beyond the tip of the flow wire. Coronary blood flow was
derived from the average peak velocity and diameter mea-
surements using the formula
Q D 5
p D2
4
~0.5 3 APV!,
where Q D 5 Doppler-derived time-average flow, D 5
vessel diameter, APV 5 time average of the spectral peak
velocity and p 5 3.14 (45). The use of the Doppler guide
wire for intravascular measurement of coronary flow velocity
has been previously validated (45,46).
After measurement of coronary blood flow, the Doppler
coronary flow wire was withdrawn, mounted on the balloon
angioplasty catheter, and then readvanced into the coronary
artery. The wire was passed across the lesion and positioned
in a distal segment of the vessel undergoing PTCA. After
the balloon was positioned across the lesion, the patients
underwent three 2-min balloon inflations separated by
5-min intervals of reperfusion (same protocol used in the
other cohort of 30 patients). Average peak velocity was
recorded continuously before, during and for 5 min after
each balloon inflation. Collateral blood flow was defined as
retrograde or persistent antegrade flow during balloon
occlusion, as previously reported (48).
Echocardiographic studies. Quantitative two-dimensional
echocardiograms were performed serially in 18 patients (9
control and 9 bradykinin-treated participants) at baseline,
after infusion of bradykinin or saline, at the end of each
balloon inflation (i.e., 110 to 120 s into the inflation) and at
5 min after each balloon deflation. The methods have been
previously described in detail (39,49). Briefly, two-
dimensional images of the left ventricle were obtained from
the apical four- and two-chamber views with a phased-array
echocardiographic machine (SONOS 1500 or 2500,
Hewlett-Packard) and a 2.5-MHz transducer. The images
were recorded on 1⁄2-inch videotape for subsequent review
and analysis. The echocardiograms were analyzed quantita-
tively for regional LV wall-motion abnormalities with the
use of a commercially available microcomputer system
(GTI, Freeland, Indianapolis, Indiana). Quantitative anal-
ysis of regional wall motion was performed from the apical
four- and two-chamber views using a centerline method
that corrects for ventricular translation. The method con-
structs 100 equidistant chords perpendicular to a line
centered between digitized LV end-diastolic and end-
systolic endocardial borders (49). One hundred equidistant
chords perpendicular to the centerline were constructed
between boundaries, which represented motion of corre-
sponding points of the LV endocardium. Chords from the
anterior wall, apex, mid septum and apical septum were
considered to be in the distribution of the left anterior
descending coronary artery (LAD). Chords in the inferior
and lateral walls were considered to be in the distribution of
the right and circumflex coronary arteries, respectively.
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These assumptions were verified by noting the distribution
of the wall-motion abnormalities during balloon inflation.
The average shortening of the chords in the distribution of
the coronary artery undergoing PTCA was determined
serially at baseline, after bradykinin or saline infusion,
during balloon inflation and 5 min into each recovery
period. The LV ejection fraction was calculated by the
biplane modified Simpson’s method (50). The echocardio-
graphic studies were analyzed by an echocardiographer
(M.F.S.) who had no knowledge of the treatment.
Statistical analysis. All data are reported as mean value 6
SEM. The ST-segment shifts, chest pain score, chordal
shortening, LV ejection fraction, coronary blood flow and
vessel diameter were analyzed with a one-way or two-way
repeated-measures ANOVA, as appropriate. Post hoc con-
trasts between groups at various time-points or between
time-points within one group were performed with the
Student t test for unpaired or paired data, as appropriate,
using the Bonferroni correction (51). The remaining con-
tinuous or dichotomous variables were compared between
the two groups using unpaired Student t tests or chi-square
tests, respectively. The echocardiographic data were ana-
lyzed with the SPSS program, version 6.1; the remaining
data were analyzed with Microsoft Excel HP, version 7.0. A
p value ,0.05 was considered statistically significant.
RESULTS
Fifteen patients in the control group and 15 in the
bradykinin-treated group met the criteria detailed under
“Methods” and had technically adequate intracoronary and
surface ECGs associated with complete resolution of isch-
emia between balloon inflations. Complete resolution of
ischemia was defined as chest pain resolution and return of
the ST-segment on the intracoronary and surface ECGs to
within 1 mm of baseline during the 5 min that elapsed
between the first, second and third balloon inflations. The
clinical features of the control and bradykinin-treated pa-
tients are outlined in Table 1. There were no significant
differences between the two groups.
Coronary angioplasty. The anatomic and hemodynamic
features of the study population are summarized in Table 2.
The PTCA was successfully performed in all 30 patients;
coronary stenosis was reduced from 81 6 3% to 20 6 1% in
the control group and from 84 6 3% to 17 6 1% in the
bradykinin-treated group. The balloon pressure was similar
in the control and bradykinin-treated groups (Table 2). The
infusion of bradykinin had no appreciable effect on heart
rate or arterial blood pressure; these two variables did not
differ between the two groups during the three inflations
(data not shown). The rate-pressure product was also
similar (Table 2). There was no ECG or enzymatic evidence
of myocardial injury in any patient.
Electrocardiographic manifestations of myocardial isch-
emia. All patients exhibited ST-segment elevation during
balloon inflation. In the control group, the ST-segment
shift was significantly greater during the first balloon infla-
tion than during the second and third inflations on both the
intracoronary ECG (23 6 3 vs. 14 6 2 and 13 6 2 mm,
respectively; Fig. 1) and the surface ECG (16 6 3 vs. 10 6
2 and 9 6 2 mm, respectively; Fig. 2). In contrast, in the
bradykinin-treated group, no differences existed in the
ST-segment shift during the first, second and third balloon
inflations, on either the intracoronary ECG (12 6 2, 11 6
2 and 11 6 2 mm, respectively; Fig. 1) or the surface ECG
(7 6 1, 7 6 1 and 7 6 1 mm, respectively; Fig. 2).
The ST-segment shift recorded on the intracoronary
ECG was significantly smaller in the bradykinin-treated
group than in the control group during the first balloon
inflation (12 6 2 vs. 23 6 3 mm [248%], p , 0.01) (Fig.
1), but did not differ significantly between the two groups
during the second and third inflations (11 6 2 vs. 14 6
2 mm and 11 6 2 vs. 13 6 2 mm, respectively; p 5 NS)
(Fig. 1). Similarly, the ST-segment shift recorded on the
surface ECG was significantly smaller in the bradykinin-
treated group than in the control group during the first
inflation (7 6 1 vs. 16 6 3 mm, respectively; p , 0.01), but
did not differ significantly between the two groups during
the second and third inflations (7 6 1 vs. 10 6 2 mm and
7 6 1 vs. 9 6 2 mm, respectively; p 5 NS) (Fig. 2).
The effect of bradykinin on the ST-segment shifts was
Table 2. Anatomic and Hemodynamic Features of the Two
Groups of Patients
Control
Group
(n 5 15)
Bradykinin-
Treated
Group
(n 5 15)
p
Value
Vessel undergoing PTCA
LAD 10 6 NS
LCx 4 6 NS
RCA 1 3 NS
Site of PTCA
Proximal third 7 7 NS
Mid-third 8 8 NS
Diameter stenosis, %
Before PTCA 81 6 3 84 6 3 NS
After PTCA 20 6 1 17 6 1 NS
Inflation pressure, atm
Inflation 1 5.8 6 0.2 5.6 6 0.4 NS
Inflation 2 5.6 6 0.2 5.7 6 0.4 NS
Inflation 3 5.9 6 0.2 5.6 6 0.4 NS
RPP (3 103)
Inflation 1 10.7 6 0.7 10.2 6 0.5 NS
Inflation 2 9.5 6 0.8 10.5 6 0.5 NS
Inflation 3 9.8 6 0.7 10.6 6 0.7 NS
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; RCA 5 right coronary artery; PTCA 5 percutaneous transluminal coronary
angioplasty; RPP 5 rate-pressure product (heart rate 3 systolic blood pressure; atm 5
atmosphere) .
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independent of the presence of a history of unstable angina.
Indeed, when the analysis was restricted to the 15 patients
with stable angina pectoris, the results were similar to those
obtained in the entire cohort. For example, during the first,
second and third balloon inflations, the intracoronary ST-
segment shift averaged 26 6 5, 14 6 3 and 14 6 3 mm,
respectively, in the eight control patients with stable angina
pectoris and 10 6 2, 9 6 3 and 10 6 2 mm, respectively, in
the seven bradykinin-treated patients with stable angina
pectoris. During the first inflation, the values in the treated
patients were significantly (p , 0.05) less than the corre-
sponding values in the control patients.
Figure 1. Individual (left panel) and average (right panel) values of ST-segment shifts on the intracoronary ECG at the end of the first,
second and third balloon inflations in control and bradykinin-treated patients. In control patients, the ST-segment shifts decreased during
the second and third inflations compared with the first. In contrast, in bradykinin-treated patients the ST-segment shifts were similar
during all three inflations. During the first inflation, the ST-segment shift was less in bradykinin-treated compared with control patients.
Values are means 6 SEM.
Figure 2. Individual (left panel) and average (right panel) values of ST-segment shifts on the surface ECG at the end of the first, second
and third balloon inflations in control and bradykinin-treated patients. In control patients, the ST-segment shifts decreased during the
second and third inflations compared with the first. In contrast, in bradykinin-treated patients the ST-segment shifts were similar during
all three inflations. During the first inflation, the ST-segment shift was less in bradykinin-treated than in control patients. Values are
means 6 SEM.
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Chest pain. In the control group, the severity of chest pain
was significantly greater during the first inflation than
during the second and third inflations (68 6 5 vs. 54 6 7
and 41 6 6 mm, respectively; Fig. 3). In contrast, in the
bradykinin-treated group, the chest pain score did not differ
significantly during the first, second and third inflations
(39 6 5, 37 6 5 and 36 6 5 mm, respectively; Fig. 3). The
chest pain score was significantly smaller in the bradykinin-
treated group than in the control group during the first
balloon inflation (243% [p , 0.01]) but not during the
second and third inflations (Fig. 3).
The effect of bradykinin on the severity of chest pain was
independent of the presence of unstable angina. Indeed, in
the 15 patients with stable angina pectoris, the chest pain
score was significantly less in the bradykinin-treated group
than in the control group during the first (247% [p ,
0.01]) and second (240% [p , 0.05]) inflation.
Echocardiographic data. In the control group, chordal
shortening in the distribution of the artery undergoing
PTCA averaged 7.9 6 0.3 mm before the infusion of
normal saline and 8.0 6 0.3 mm after the infusion. In the
bradykinin-treated group, chordal shortening averaged
7.9 6 0.4 mm before the infusion and 7.6 6 0.3 mm after
the infusion. Thus, administration of bradykinin had no
appreciable effect on regional LV wall motion. In the
control group, chordal shortening in the territory subserved
by the occluded artery decreased markedly (by 65 6 5%)
during the first balloon inflation and recovered 5 min after
deflation (Fig. 4). During the second and third inflations,
the decrease in chordal shortening was significantly less than
during the first inflation (252 6 6% and 245 6 7%,
respectively; each p , 0.05 vs. first inflation) (Fig. 4). In the
bradykinin-treated group, the reduction in chordal shorten-
ing during the first inflation was significantly smaller than in
the control group (248 6 6% vs. 265 6 5%, p , 0.05 [Fig.
4]). Furthermore, in contrast to the control group, in the
bradykinin-treated group there were no significant differ-
ences in chordal shortening during the first, second and
third balloon inflations (248 6 6%, 241 6 4% and 237 6
7%, respectively) (Fig. 4).
Left ventricular ejection fraction did not change signifi-
cantly before and after the intracoronary infusion of normal
saline (65 6 2% and 68 6 2%, respectively) or bradykinin
(61 6 2% and 62 6 2%, respectively). In the control group,
LV ejection fraction decreased to 40 6 1%, 43 6 1% and
47 6 1% during the first, second and third inflations,
respectively (p 5 NS). In the bradykinin-treated group, LV
ejection fraction fell to 45 6 2%, 48 6 3% and 47 6 2%
during the first, second and third inflations, respectively
(p 5 NS).
Coronary blood flow. In a separate cohort of seven pa-
tients not included in the studies of ST-segment shifts and
chest pain, selective infusion of bradykinin into the artery
undergoing PTCA resulted in a significant increase in
coronary blood flow and coronary diameter, but these
changes were short-lived and subsided completely within
10 min from the discontinuation of the infusion. Average
coronary artery blood flow increased from 73 6 15 ml/min
at baseline to 170 6 39 ml/min immediately after bradyki-
Figure 3. Individual (left panel) and average (right panel) values of chest pain score during the first, second and third balloon inflations
in control and bradykinin-treated patients. In control patients, the chest pain score decreased progressively from the first to the third
inflation. In contrast, in bradykinin-treated patients the chest pain score did not change significantly during the three inflations. During
all three inflations, the chest pain score was significantly less in bradykinin-treated compared with control patients. Values are means 6
SEM.
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nin infusion and returned to baseline levels (62 6
14 ml/min) 10 min after the infusion of bradykinin (Fig. 5).
Similarly, coronary artery diameter increased from 2.81 6
0.26 mm at baseline to 3.08 6 0.27 mm at the end of the
bradykinin infusion and returned to baseline levels (2.69 6
0.26 mm) 10 min after the infusion of bradykinin (Fig. 6).
Collateral blood flow during balloon inflation (evidenced by
retrograde flow in the occluded artery) was noted only in
one patient who had subtotal stenosis of the LAD. In the
other patients, no appreciable antegrade or retrograde flow
Figure 4. Chordal shortening in the ischemic/reperfused LV region at baseline (before bradykinin or saline infusion), after infusion, at the
end of the first, second and third balloon inflations (INFL-1, INFL-2 and INFL-3), immediately before the second and third inflations
(PRE-INFL-2 and PRE-INFL-3) and 5 min after the third inflation in control and bradykinin-treated patients (n 5 9 in each group).
Chordal shortening was determined by quantitative two-dimensional echocardiography using the centerline method (see “Methods”) and
expressed as a percent of baseline values. In control patients, the decrease in chordal shortening was significantly less during the second
inflation and third inflation compared with the first inflation. In contrast, in bradykinin-treated patients, chordal shortening did not change
significantly during the three inflations; furthermore, during the first inflation, chordal shortenings were less in bradykinin-treated patients
than in control patients. Values are means 6 SEM.
Figure 5. Individual (left panel) and average (right panel) values
of coronary artery blood flow before the infusion of bradykinin
(baseline), immediately after the infusion of bradykinin (BK) and
10 min after the infusion of bradykinin (post-BK). Coronary flow
increased significantly during the infusion of bradykinin but
returned to baseline values within 10 min after the infusion. Values
are means 6 SEM.
Figure 6. Individual (left panel) and average (right panel) values
of minimal luminal diameter before the infusion of bradykinin
(baseline), immediately after the infusion of bradykinin (BK) and
10 min after the infusion of bradykinin (post-BK). Minimal
luminal diameter increased significantly during the infusion of
bradykinin but returned to baseline values within 10 min after the
infusion. Values are means 6 SEM.
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was observed during the three balloon inflations. The fact
that the protective effect of bradykinin (Figs. 1 to 4) was still
manifest after the hyperemic response had disappeared (Fig.
5) indicates that it was not due to recruitment of collateral
vessels.
Adverse effects of bradykinin. The infusion of bradykinin
was well tolerated by the patients, and no significant adverse
effects were noted. All patients developed mild chest pain
during the infusion of bradykinin, which resolved promptly
after the end of the infusion. Bradykinin had no effect on
heart rate and blood pressure. Therefore, it appears that this
dose of bradykinin can be safely infused in patients before
PTCA.
DISCUSSION
Experimental evidence indicates that ischemic PC is a
multifactorial cellular response initiated by the activation of
various membrane receptors, which appear to act via a
common signal transduction pathway (3,4). Studies in
patients undergoing PTCA have shown that ischemic PC
can be triggered by the activation of adenosine A1
(34,35,39) and alpha1 adrenergic (38) receptors and is
mediated by the opening of KATP channels (33). However,
one important mechanism that has not yet been evaluated in
humans in vivo is the activation of the bradykinin B2
receptor.
Salient findings. The present study demonstrates that
intracoronary infusion of bradykinin before PTCA en-
hances the tolerance of the heart to subsequent ischemia in
a manner analogous to that observed during ischemic PC.
Specifically, pretreatment with bradykinin resulted in a 48%
decrease in the intracoronary ST-segment shift and a 43%
decrease in the chest pain score during the first balloon
inflation, indicating that the severity of ischemic injury was
significantly attenuated. The ST-segment shift and the
chest pain score noted during the first balloon inflation in
bradykinin-treated patients were indistinguishable from
those observed during the third inflation in control patients,
indicating that the degree of protection afforded by brady-
kinin was comparable to that afforded by prior exposure to
brief ischemia in the control group. This conclusion is
further corroborated by the observation that in control
patients the ST-segment shift, the severity of chest pain and
the magnitude of regional LV wall-motion abnormalities
decreased after the first balloon inflation, whereas in
bradykinin-treated patients no significant decrease occurred
in any of these variables during the second or third inflation
compared with the first (that is, the ischemic PC effect
associated with the first and second inflations failed to
enhance the protection induced by pretreatment with bra-
dykinin). Thus, it appears that in bradykinin-treated pa-
tients, the myocardium was already “maximally” precondi-
tioned during the first balloon inflation.
The protection afforded by bradykinin represents a form
of pharmacologic PC rather than simply an anti-ischemic
effect of the drug, because it was observed 10 min after the
end of the infusion, at a time when bradykinin was no
longer present and the coronary vasodilator effects of this
peptide had completely resolved. Furthermore, the protec-
tive effects of bradykinin cannot be ascribed to a negative
inotropic effect (possibly secondary to increased NO pro-
duction [7,9,10]), because the infusion of bradykinin pro-
duced no changes in regional LV wall motion.
The finding that pretreatment with bradykinin elicits a
PC-like effect in patients undergoing PTCA is compatible
with the hypothesis that endogenous release of this sub-
stance may contribute to ischemic PC in humans. Previous
studies have demonstrated that bradykinin plays a role in
ischemic PC in various experimental models (6–13). How-
ever, to the best of our knowledge, the present study is the
first evidence that bradykinin preconditions human myocar-
dium against ischemia in vivo.
Roles of adenosine and bradykinin in preconditioning.
We (39) have previously reported that intracoronary infu-
sion of adenosine mimics the cardioprotective effects of
ischemic PC in patients undergoing PTCA—the same
clinical setting utilized in this investigation. The present
finding that a different agonist elicits cardioprotective effects
comparable to those of adenosine (39) has important patho-
physiologic implications for the mechanism of PC in
humans. Experimental studies have demonstrated that sev-
eral G-protein-coupled membrane receptors can trigger a
signaling cascade that culminates in enhanced resistance to
ischemic injury, presumably via a common effector pathway,
which appears to involve the activation of protein kinase C
and the opening of KATP channels (3,4). Our observations
that a comparable degree of protection can be achieved with
activation of either adenosine or bradykinin receptors sup-
ports the existence of a similar paradigm in the intact
human heart and suggests that ischemic PC in patients
involves multiple membrane receptors.
It has been proposed (11) that this multifactorial nature
of the PC response serves to enhance its effectiveness,
because brief ischemia is associated with the release of
several ligands potentially capable of evoking the response.
Depending on the intensity of the ischemic stimulus, these
ligands may or may not be released in sufficient quantity to
achieve the “threshold” stimulation necessary to trigger
ischemic PC. If the PC stimulus is relatively mild, stimu-
lation of multiple membrane receptors will be necessary to
achieve the threshold. Conversely, a more robust PC stim-
ulus may release greater quantities of ligands, such that each
(or some) of them is sufficient to trigger ischemic PC.
Possible role of collateral flow. It could be argued that, in
control patients, the alleviation of ischemia observed during
subsequent balloon inflations was due to collateral recruit-
ment rather than ischemic PC. Considerable evidence,
however, suggests that this was not the case (52). For
example, it has been found that the development of toler-
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ance to ischemia during PTCA does not correlate with
collateral function, as assessed by myocardial contrast echo-
cardiography (37) and by measurements of peak flow
velocity in the contralateral artery (38). Using a pressure-
derived collateral flow index, only 30% of the observed
variation in intracoronary ECG ST-segment shifts could be
accounted for by collateral recruitment (53). That investi-
gation (53) differed from most studies of PTCA because
there was no evidence of enhanced tolerance to ischemia on
the second inflation versus the first.
It could also be argued that bradykinin induced cardio-
protection simply by improving collateral perfusion to the
ischemic region. This possibility, however, is unlikely for
several reasons. First, the coronary flow measurements
demonstrate that the bradykinin-induced vasodilation sub-
sided completely within 10 min of the end of the infusion
(Figs. 5 and 6), so that any increase in collateral flow, even
if it occurred, should have resolved before the first balloon
inflation (which was performed 10 min after the end of
bradykinin infusion).
Second, a hypothetical bradykinin-induced increase in
collateral flow would require that the collateral vessels be
dilated in their entire length, including the portion of these
vessels that is outside of the ischemic coronary bed (i.e., the
portion that is within the adjacent coronary beds not infused
with bradykinin), because dilation of only a portion of a
collateral vessel would not significantly reduce total resis-
tance in that vessel. Because bradykinin was infused intra-
coronarily, however, only the portion of the collateral vessels
contained within the ischemic vascular bed was exposed to
this agent. Finally, evidence of collateral circulation during
PTCA has been found only in a minority of patients
(31,37,38,54), whereas the protective effects of bradykinin
(as evidenced by the lack of decrease in ST-segment shift
after the first inflation) were observed in most of the patients
studied in the present investigation (Figs. 1 and 2).
Previous studies. The only study that has examined the
role of bradykinin in ischemic PC in human myocardium
has been performed in an in vitro model in which isolated
right atrial trabeculae were submitted to simulated ischemia
(substrate-free hypoxia with rapid pacing) followed by
reoxygenation (21). It was found that the protection af-
forded by the combination of subthreshold ischemia and
ACE inhibitors was abolished by the bradykinin B2 receptor
antagonist HOE 140, suggesting that ACE inhibitors
augment ischemic PC via B2 receptor activation (21). The
present investigation expands upon this previous study by
demonstrating 1) that bradykinin preconditions the intact
human heart in vivo, 2) that it protects ventricular myocar-
dium (as opposed to atrial myocardium) and 3) that it is
effective in alleviating ischemia (as opposed to substrate-free
hypoxia).
The exact cellular mechanism whereby bradykinin in-
duces a PC-like state remains unclear. Goto et al. (11) have
shown that the PC-like effect of bradykinin in rabbit hearts
could be abolished by the protein kinase C (PKC) inhibitors
polymixin B and staurosporine, indicating that bradykinin
induces protection via a PKC-mediated signaling pathway.
This is the same signaling pathway that is activated by
adenosine (3,4), which provides a plausible explanation for
the fact that both adenosine and bradykinin can induce
comparable protection in experimental animals (11) and in
patients undergoing PTCA, as shown in our previous study
(39) and in the current study.
Implications. In conclusion, this study demonstrates that
in patients with coronary artery disease, pretreatment with
bradykinin confers significant protection during a subse-
quent coronary occlusion, as evidenced by an attenuation of
the electrocardiographic, mechanical and symptomatic
manifestations of ischemia. To our knowledge, this is the
first indication that bradykinin protects human myocardium
against ischemia in vivo. Judging from the variables mea-
sured in the present investigation, the magnitude of brady-
kinin’s cardioprotective actions appears to be equivalent to
that of ischemic PC.
These results have pathophysiologic and therapeutic im-
plications. From a pathophysiologic standpoint, they sug-
gest that bradykinin may play a role in ischemic PC in
humans, because this peptide has been shown to be pro-
duced during brief coronary occlusions in patients (55). It is
important to note that the notion that bradykinin exerts
cardioprotective effects provides a possible explanation for
the known anti-ischemic actions of ACE inhibitors. It is
well established that ACE is present in the vascular endo-
thelium as well as in the parenchyma of many tissues,
including the heart (28). Also, ACE-induced degradation
of bradykinin appears to occur in many tissues, including the
myocardium (23). Studies of ACE inhibitors (24–26) have
demonstrated that these agents cause a reduction of isch-
emic events that cannot be explained solely by improved
hemodynamics (29). The present finding that bradykinin
attenuates the severity of ischemic injury is compatible with
the hypothesis that the anti-ischemic effects of ACE inhib-
itors may be mediated, at least in part, by enhanced tissue
kinin levels.
From a practical standpoint, pretreatment with bradyki-
nin may be a useful prophylactic measure in patients
undergoing PTCA who are at risk for complications. For
example, patients with substantially impaired LV function
or large regions of myocardium subtended by the target
vessel can develop severe hemodynamic compromise or
refractory arrhythmias in the event of abrupt vessel closure.
Because such patients are likely to suffer irreversible myo-
cardial or end-organ damage due to hypotension and
ischemia and might not be expected to survive the typical
130–150-min time period before reperfusion by surgical
revascularization, there is a need to develop strategies that
can lessen the severity of ischemic myocardial damage.
Although adenosine can induce a cardioprotective effect
comparable to that of bradykinin (39), infusion of adenosine
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into the right or a dominant left circumflex artery is
hazardous because it may cause bradyarrhythmias or hypo-
tension as a result of sinus bradycardia and/or atrioventric-
ular block. Bradykinin is devoid of these side effects and
therefore provides an alternative form of protection for
those patients in whom intracoronary adenosine is contra-
indicated.
Reprint requests and correspondence: Dr. Roberto Bolli, Divi-
sion of Cardiology, University of Louisville, Louisville, Kentucky
40292. E-mail: rbolli@louisville.edu.
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